118 related articles for article (PubMed ID: 18183354)
1. Short term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate cancer.
Agirbasli M; Baykan OA; Tekin A; Sengor F; Cincin AA; Demir M; Vaughan DE
J Thromb Thrombolysis; 2009 Feb; 27(2):172-4. PubMed ID: 18183354
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
3. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.
Agirbasli M; Inanc N; Baykan OA; Direskeneli H
Clin Exp Rheumatol; 2006; 24(5):580-3. PubMed ID: 17181930
[TBL] [Abstract][Full Text] [Related]
4. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
5. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
6. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
Lawrentschuk N; Fernandes K; Bell D; Barkin J; Fleshner N
J Urol; 2011 Mar; 185(3):848-54. PubMed ID: 21239017
[TBL] [Abstract][Full Text] [Related]
8. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
9. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
Cancer; 2005 Apr; 103(8):1615-24. PubMed ID: 15742331
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.
Raja T; Sud R; Addla S; Sarkar KK; Sridhar PS; Talreja V; Jain M; Patil K
Indian J Cancer; 2022 Mar; 59(Supplement):S142-S159. PubMed ID: 35343198
[TBL] [Abstract][Full Text] [Related]
11. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
12. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease.
Lindoff C; Petersson F; Samsioe G; Astedt B
Int J Fertil Menopausal Stud; 1994; 39(3):133-9. PubMed ID: 7920748
[TBL] [Abstract][Full Text] [Related]
14. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
Agirbasli M; Cincin A; Baykan OA
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
[TBL] [Abstract][Full Text] [Related]
16. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
17. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
[TBL] [Abstract][Full Text] [Related]
18. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
19. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
Smith MR; Boyce SP; Moyneur E; Duh MS; Raut MK; Brandman J
J Urol; 2006 Jan; 175(1):136-9; discussion 139. PubMed ID: 16406890
[TBL] [Abstract][Full Text] [Related]
20. The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
Hasui Y; Marutsuka K; Nishi S; Kitada S; Osada Y; Sumiyoshi A
Prostate; 1992; 21(1):35-9. PubMed ID: 1641370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
